CA-SAMBANOVA-SYSTEMS
26.10.2021 15:02:06 CEST | Business Wire | Press release
SambaNova Systems , the company building the industry’s most advanced software, hardware and services to run AI applications, today announced that its AI membership program for the enterprise, ELEVAITE , is now open for applications. The program is designed to lead select cohorts of enterprises into the AI-enabled future leveraging SambaNova’s unmatched AI technology, solutions, expertise, and proven success while addressing the biggest challenges of starting and scaling an AI program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026005330/en/
“The emergence of AI and its expected impact on the Global 2000 – akin to the impact of the internet – is upon us,” said Rodrigo Liang, co-founder and CEO of SambaNova. “For those with a desire to embrace the transformational power of AI, there are huge opportunities. With SambaNova ELEVAITE, enterprises will receive unmatched education and technical guidance that directly supports successful AI initiatives from conception to deployment, scalability, and ROI with market visibility for their technology leadership.”
Leaders across industries such as financial services, energy, manufacturing, healthcare, and more realize it is time to apply AI to their organization’s data resources. ELEVAITE is uniquely designed to accelerate selected cohort enterprises’ deployment of the most advanced and performant AI software, hardware, and services available for AI, machine learning, and deep learning.
As an ELEVAITE member, SambaNova teams will work with businesses to determine the most impactful AI technologies based on SambaNova’s experience and deep understanding of enterprise needs to deliver business impact. These include use cases for Natural Language Processing, Vision, and Recommendation.
“Enterprises well suited to participate in ELEVAITE are those that recognize the imperative to drive focus on new initiatives when looking to accelerate AI capabilities inside organizations,” said Marshall Choy, VP of Product at SambaNova. “Working together, ELEVAITE members and SambaNova will accelerate the deployment and scalability inside their enterprises.”
“ELEVAITE membership is designed to deliver unmatched education and awareness on a personal and cohort basis to accelerate enterprises’ transformation to an AI-Enabled organization,” said Amy Love, Chief Marketing Officer at SambaNova. “The program also furthers the market-leading standing of the selected companies by presenting them as leaders in their field.”
ELEVAITE members receive access to three categories of benefits:
- Unmatched Collaboration for Success: By providing customized scoping, implementation and scaling of AI solutions, SambaNova’s dedicated technical and account leads will be with you every step of the way.
- Institutionalized Skills and Knowledge : SambaNova founders, senior executives, board members, technologists, and industry luminaries will educate participating organizations to deliver the resources required to implement AI initiatives and develop new AI skills.
- ELEVAITED Visibility Driving Enterprise Value: With access to the SambaNova VisionAIres program, participants can increase the visibility of their AI initiatives, develop thought leadership and enhance their company’s reputation through media exposure.
ELEVAITE reduces the risk for enterprises and commits to scalable deployment by providing access to unique SambaNova resources and knowledge to ensure they are successful with AI. Members have access to SambaNova’s turnkey platform, including Dataflow-as-a-Service™, an extensible AI services platform, and DataScale®, an integrated software and hardware platform delivering unrivaled performance, accuracy, scale and ease of use built on SambaNova’s Systems Reconfigurable Dataflow Architecture™. This eliminates the need for massive data science staffing, significantly reducing the cost of investment.
To learn more, schedule an executive conversation or to apply for the program, visit sambanova.ai/elevaite . The selection process will occur this fall and the first cohort program will begin in January 2022.
About SambaNova Systems:
SambaNova Systems is an AI innovation company that empowers organizations to deploy best-in-class solutions for natural language processing, computer vision, recommendation systems, and AI for science with confidence. SambaNova's flagship offering, Dataflow-as-a-Service™, helps organizations rapidly deploy AI in days, unlocking new revenue and boosting operational efficiency. SambaNova's DataScale® is an integrated software and hardware system using Reconfigurable Dataflow Architecture™, along with open standards and user interfaces. Headquartered in Palo Alto, California, SambaNova Systems was founded in 2017 by industry luminaries and hardware and software design experts from Sun/Oracle and Stanford University. Investors include SoftBank Vision Fund 2, funds and accounts managed by BlackRock, Intel Capital, GV, Walden International, Temasek, GIC, Redline Capital, Atlantic Bridge Ventures, Celesta, and several others. For more information, please visit us at sambanova.ai or contact us at info@sambanova.ai . Follow SambaNova Systems on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005330/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom